<DOC>
	<DOCNO>NCT01638598</DOCNO>
	<brief_summary>Safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) BI 1021958 single rise dos ( SRD ) healthy Asian male volunteer</brief_summary>
	<brief_title>Single Rising Oral Doses BI 1021958 Healthy Chinese Japanese Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male base upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead ECG , clinical laboratory test 2 . Chinese ethnicity , Japanese ethnicity accord follow criteria Japanese ; bear Japan , current Japanese passport holder , live outside Japan &lt; 5 year , parent grandparent born Japan Chinese ; ethnic Chinese , born China ethnic Chinese born outside China , descendent 4 ethnic Chinese grandparent bear China 3 . Age within range 20 45 year 4 . Body mass index within range 18.5 25 kg/m2 5 . Signed date write informed consent prior admission study accordance GCP local legislation . Exclusion criterion : 1 . Any finding medical examination ( include Blood Pressure , Pulse Rate , ECG Safety laboratory ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Surgery gastrointestinal tract ( except appendectomy ) 5 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 6 . History relevant orthostatic hypotension , faint spell blackout . 7 . Chronic relevant acute infection 8 . History relevant allergy/hypersensitivity ( include allergy/hypersensitivity study drug excipients ) 9 . Intake drug long halflife ( 24 hour ) within least 1 month less 10 halflives respective drug prior administration 10 . Use drug might reasonably influence result trial prolong QT/QTc interval ( base knowledge time protocol preparation ) within 10 day prior administration 11 . Participation another trial investigational drug administration within 2 month prior administration 12 . Smoker ( 10 cigarette 3 cigar 3 pipes/day ) 13 . Inability refrain smoke trial day 14 . Alcohol abuse ( 30 g/day ) 15 . Drug abuse 16 . Blood donation ( 100 mL within 4 week prior administration ) 17 . Any laboratory value outside reference range clinical relevance 18 . Inability comply dietary regimen trial site 19 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval 450 m ) , heart rate outside 45 90 bpm , relevant ECG finding screen 20 . A history additional risk factor TdP ( e.g. , heart failure , hypokalemia , family history long QT Syndrome ) 21 . Subjects consider unsuitable inclusion investigator , e.g . consider able understand comply study requirement , condition opinion investigator would allow safe participation study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>